The Trump administration’s proposal to eliminate pharma-to-PBM rebates in Medicare Part D and Medicaid managed care organizations has the potential to “significantly lower out-of-pocket prescription drug costs,” the authors of a recent opinion piece published on the Morning Consult write.
The proposal aims look to shift the savings enjoyed by PBMs directly to patients.
“This approach would benefit the sickest and most financially vulnerable among us, including people being treated for cancer, hepatitis C, multiple sclerosis, rheumatoid arthritis and other serious illness, the authors, University of Michigan Center for Value-Based Insurance Design Director Mark Fendrick and Patient Access Network Foundation CEO Dan Klein write.
To read the full article on the Morning Consult, click here.
